Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Agnieszka Blum, Despina Bazou, Peter O’Gorman Department of Hematology, Mater Misericordiae University Hospital, Dublin, UK Abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma...
Enregistré dans:
Auteurs principaux: | Blum A, Bazou D, O'Gorman P |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/5ba3e1320cb1480eaabafb1d21a824b7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
par: Bhutani D, et autres
Publié: (2017) -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
par: Gupta VA, et autres
Publié: (2021) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
par: Angelo Maiolino, et autres
Publié: (2021) -
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
par: Faiman B, et autres
Publié: (2016) -
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
par: Edvan de Queiroz Crusoé, et autres
Publié: (2021)